Hyderabad pharma maker of APIs, formulation intermediates, finished dosages and peptide CDMO services.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 25 | 25 | 25 | 24 | 24 | 24 | 24 | 25 |
| Reserves | 1.8k | 2.1k | 2.6k | 2.8k | 3.2k | 3.7k | 4.0k | 5.1k |
| Borrowings | 892 | 849 | 1.1k | 1.1k | 1.3k | 1.5k | 1.8k | 1.5k |
| Other Liabilities | 487 | 690 | 819 | 932 | 957 | 1.1k | 1.2k | 1.1k |
| Total Liabilities | 3.2k | 3.7k | 4.5k | 4.9k | 5.5k | 6.2k | 6.9k | 7.7k |
| AssetsFixed Assets | 1.2k | 1.3k | 1.5k | 1.9k | 2.1k | 2.4k | 2.8k | 3.3k |
| CWIP | 294 | 239 | 356 | 239 | 272 | 440 | 702 | 410 |
| Investments | 19 | 19 | 20 | 21 | 22 | 22 | 1 | 1 |
| Other Assets | 1.7k | 2.1k | 2.6k | 2.7k | 3.1k | 3.3k | 3.4k | 4.0k |
| Total Assets | 3.2k | 3.7k | 4.5k | 4.9k | 5.5k | 6.2k | 6.9k | 7.7k |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (25.9×) and current (33.8×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 3.5% growth and a 26× exit, ₹881 only delivers your return if you pay ₹336. The price is currently baking in 23% growth.
EPS grows 3.5%/yr for 5 years, then fades to 6% over 2, exits at 26×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 3.5% | 26.94 |
| FY28 | 3.5% | 27.88 |
| FY29 | 3.5% | 28.86 |
| FY30 | 3.5% | 29.87 |
| FY31 | 3.5% | 30.92 |
| FY32 | 4.8% ·fade | 32.38 |
| FY33 | 6.0% ·fade | 34.33 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.